Categories AlphaGraphs, Earnings, Technology
Earnings: Highlights of BlackBerry’s (BB) Q2 2023 results
Smartphone company BlackBerry Limited (NYSE: BB) has reported total revenues of $168 million for the second quarter of 2023, compared to $175 million in the same period last year.
During the three-month period, the tech firm incurred a net loss of $54 million or $0.10 per share, compared to a loss of $144 million or $0.25 per share in the prior-year quarter. Second-quarter adjusted loss, on a per-share basis, was $0.05 per share, compared to a loss of $0.06 per share in the same period of last year.
Check this space to read management/analysts’ comments on BlackBerry’s Q2 2023 earnings
“Our IoT business continues to gain market share, and design-phase revenue remained at near-record levels. A major design win in the quarter was with Volkswagen, who chose QNX for their new VW.OS, to be deployed across all Volkswagen group brands. IVY remains firmly on track, with the latest product release in August, proof of concept trials progressing well, and the IVY fund continuing to invest in exciting ecosystem partners,” said John Chen, CEO of BlackBerry.
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Infographic: Highlights of DocuSign’s (DOCU) Q1 2024 results
DocuSign, Inc. (NASDAQ: DOCU), a leading provider of electronic signature solutions, Thursday reported first-quarter earnings. It also provided guidance for the second quarter and fiscal 2024. The company's top line
Macy’s (M): A few points to consider if you have an eye on this retailer
Shares of Macy’s, Inc. (NYSE: M) stayed in red on Thursday. The stock has dropped 22% year-to-date and 32% over the past 12 months. The retailer witnessed sales and profit
Ocean Biomedical’s scientific co-founder Dr. Jonathan Kurtis gets new patent for malaria vaccine
Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharmaceutical company focused on clinical programs in oncology, fibrosis, and infectious disease, Thursday said its scientific co-founder Dr. Jonathan Kurtis received a new patent